Structure of a class C GPCR metabotropic glutamate receptor 1 bound to an allosteric modulator

Science

Volumn 344, Issue 6179, 2014, Pages 58-64

  Wu, Huixian ^a   Wang, Chong ^a   Gregory, Karen J ^b,c   Han, Gye Won ^a   Cho, Hyekyung P ^b   Xia, Yan ^b   Niswender, Colleen M ^b   Katritch, Vsevolod ^a   Meiler, Jens ^b   Cherezov, Vadim ^a   Conn, P Jeffrey ^b   Stevens, Raymond C ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c MONASH UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

4 FLUORO N [ 4 [ 6 (ISOPROPYLAMINO)PYRIMIDIN 4 YL]THIAZOL 2 YL] N METHYLBENZAMIDE; BENZAMIDE DERIVATIVE; CHOLESTEROL; DIMER; G PROTEIN COUPLED RECEPTOR; GLUTAMIC ACID; MEMBRANE PROTEIN; METABOTROPIC RECEPTOR 1; METABOTROPIC RECEPTOR ANTAGONIST; SEVEN TRANSMEMBRANE PROTEIN; UNCLASSIFIED DRUG; 4-FLUORO-N-(4-(6-(ISOPROPYLAMINO)PYRIMIDIN-4-YL)-1,3-THIAZOL-2-YL)-N-METHYLBENZAMIDE; LIGAND; METABOTROPIC GLUTAMATE RECEPTOR TYPE 1; METABOTROPIC RECEPTOR; THIAZOLE DERIVATIVE;

CRYSTAL STRUCTURE; MEMBRANE; MUTAGENICITY; NEUROLOGY; PROTEIN; SIGNALING;

ALLOSTERISM; ARTICLE; BINDING SITE; CONTROLLED STUDY; CRYSTAL STRUCTURE; CRYSTALLOGRAPHY; DIMERIZATION; DRUG BINDING; EXTRACELLULAR MATRIX; IN VITRO STUDY; LIGAND BINDING; MOLECULAR MODEL; MUTAGENESIS; NEUROMODULATION; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; STRUCTURE ACTIVITY RELATION; AMINO ACID SEQUENCE; CHEMICAL PHENOMENA; CHEMICAL STRUCTURE; CHEMISTRY; HUMAN; METABOLISM; MOLECULAR GENETICS; MUTATION; PROTEIN CONFORMATION; PROTEIN MULTIMERIZATION; PROTEIN SECONDARY STRUCTURE; PROTEIN TERTIARY STRUCTURE; X RAY CRYSTALLOGRAPHY;

ALLOSTERIC REGULATION; ALLOSTERIC SITE; AMINO ACID SEQUENCE; BENZAMIDES; BINDING SITES; CHOLESTEROL; CRYSTALLOGRAPHY, X-RAY; HUMANS; HYDROPHOBIC AND HYDROPHILIC INTERACTIONS; LIGANDS; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; MUTATION; PROTEIN CONFORMATION; PROTEIN MULTIMERIZATION; PROTEIN STRUCTURE, SECONDARY; PROTEIN STRUCTURE, TERTIARY; RECEPTORS, METABOTROPIC GLUTAMATE; STRUCTURE-ACTIVITY RELATIONSHIP; THIAZOLES;

EID: 84897580006     PISSN: 00368075     EISSN: 10959203     Source Type: Journal    
DOI: 10.1126/science.1249489     Document Type: Article

References (37)

1. M. C. Lagerström, H. B. Schiöth, Nat. Rev. Drug Discov. 7, 339-357 (2008).
2. J. Kniazeff, L. Prézeau, P. Rondard, J. P. Pin, C. Goudet, Pharmacol. Ther. 130, 9-25 (2011).
3. T. Muto, D. Tsuchiya, K. Morikawa, H. Jingami, Proc. Natl. Acad. Sci. U.S.A. 104, 3759-3764 (2007).
4. K. M. Houamed et al., Science 252, 1318-1321 (1991).
5. M. Masu, Y. Tanabe, K. Tsuchida, R. Shigemoto, S. Nakanishi, Nature 349, 760-765 (1991).
6. S. Nakanishi, Science 258, 597-603 (1992).
7. C. M. Niswender, P. J. Conn, Annu. Rev. Pharmacol. Toxicol. 50, 295-322 (2010).
8. G. Dölen, R. L. Carpenter, T. D. Ocain, M. F. Bear, Pharmacol. Ther. 127, 78-93 (2010).
9. A. Satoh et al., Bioorg. Med. Chem. Lett. 19, 5464-5468 (2009).
10. See supplementary materials on Science Online.
11. V. Katritch, V. Cherezov, R. C. Stevens, Annu. Rev. Pharmacol. Toxicol. 53, 531-556 (2013).
12. K. Palczewski et al., Science 289, 739-745 (2000).
13. F. Y. Siu et al., Nature 499, 444-449 (2013).
14. K. Hollenstein et al., Nature 499, 438-443 (2013).
15. C. Wang et al., Nature 497, 338-343 (2013).
16. H. Wu et al., Nature 485, 327-332 (2012).
17. B. Wu et al., Science 330, 1066-1071 (2010).
18. J. A. Ballesteros, H. Weinstein, Methods Neurosci. 25, 366-428 (1995).
19. 7.50. The numbering of other residues in each helix is counted relative to the X.50 position according to the B&W numbering system.
20. Superscripts refer to the B&W numbering for class A GPCRs and were transplanted to class C GPCRs on the basis of structural superposition.
21. G. Suzuki et al., J. Pharmacol. Exp. Ther. 321, 1144-1153 (2007).
22. J. Fukuda et al., Neuropharmacology 57, 438-445 (2009).
23. P. Malherbe et al., Mol. Pharmacol. 64, 823-832 (2003).
24. S. Litschig et al., Mol. Pharmacol. 55, 453-461 (1999).
25. A. Pagano et al., J. Biol. Chem. 275, 33750-33758 (2000).
26. A. Surin, S. Pshenichkin, E. Grajkowska, E. Surina, J. T. Wroblewski, Neuropharmacology 52, 744-754 (2007).
27. P. Malherbe et al., J. Neurochem. 98, 601-615 (2006).
28. Y. Chen, C. Goudet, J. P. Pin, P. J. Conn, Mol. Pharmacol. 73, 909-918 (2008).
29. C. Mølck et al., Mol. Pharmacol. 82, 929-937 (2012).
30. K. J. Gregory et al., Mol. Pharmacol. 82, 860-875 (2012).
31. K. J. Gregory et al., Mol. Pharmacol. 83, 991-1006 (2013).
32. F. Xu et al., Science 332, 322-327 (2011).
33. N. Kunishima et al., Nature 407, 971-977 (2000).
34. S. Huang et al., Proc. Natl. Acad. Sci. U.S.A. 108, 15480-15485 (2011).
35. E. Doumazane et al., Proc. Natl. Acad. Sci. U.S.A. 110, E1416-E1425 (2013).
36. C. Eroglu, B. Brugger, F. Wieland, I. Sinning, Proc. Natl. Acad. Sci. U.S.A. 100, 10219-10224 (2003).
37. J. Meiler, D. Baker, Proteins 65, 538-548 (2006).